Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Scinai's CDMO subsidiary signed a definitive $5.1 million development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company covering CMC development and clinical manufacturing for an investigational oncology product. Following the signing, Committed Customer Orders reached approximately $7.6 million, up roughly 300% from $1.9 million at year-end 2025, with services contributing to revenue across 2026 and 2027. An additional $5.85 million of potential clinical manufacturing for late 2027 through mid-2028 remains uncommitted, and future commercial manufacturing would require a separate agreement.
Key figures
- Deal Value Usd
- 5100000
- Committed customer orders
- $7.6 million (up ~300% from $1.9 million at year-end 2025)
- Potential uncommitted fees
- $5.85 million (late 2027 through H1 2028)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.